Table 4.

Tumor marker expression level by LMP1 status among EBV+ DLBCL cases

EBV+ DLBCL LMP1 expression statusTumor marker scorea, mean (SD)
BCL6BLIMP1LMO2CD30
 LMP− (n = 14)0.79 (1.31)1.08 (1.44)0.93 (1.00)0.77 (1.17)
 LMP+ (n = 8)0.13 (0.35)0.25 (0.71)1.38 (1.06)3.38 (1.19)
BCL2BAXCyclin D2Cyclin E
 LMP−0.92 (1.04)1.64 (1.65)0.07 (0.27)1.71 (1.33)
 LMP+2.00 (1.31)2.86 (0.90)0 (0)1.50 (1.41)
Ki-67FOXP1P53Survivin
 LMP−2.38 (0.65)1.07 (1.49)0.79 (1.19)2.21 (1.48)
 LMP+2.13 (0.64)0.63 (0.74)0.75 (0.71)3.71 (0.76)
P27MMP9GAL3SKP2
 LMP−0.79 (0.80)1.92 (1.75)1.08 (1.19)0.50 (1.09)
 LMP+0.38 (0.52)2.75 (1.58)1.75 (1.75)0.25 (0.46)
PKC-beta 2MUM1cMYCCD43
 LMP−2.43 (1.55)2.79 (1.42)2.00 (1.52)1.69 (1.97)
 LMP+4.00 (0)2.00 (1.31)1.25 (1.39)1.25 (1.83)
CD10CD44CD21
 LMP−1.29 (1.59)2.62 (1.04)0 (0)
 LMP+0.50 (0.53)2.88 (1.46)0 (0)
  • aTumor marker score: 0, 0%–9%; 1, 10%–24%; 2, 25%–49%; 3, 50%–74%; and 4, ≥75% of DLBCL cells stained positive for the marker.